TrialThe Journal of infectious diseases2010

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jeffrey M Jacobson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.